title: [A paradox and three egnimas about the role of BRCA1 in breast and ovarian cancers].
abstract: More than 50% of the hereditary forms are associated with germ line mutation in either BRCA1 or BRCA2 genes (BReast CAncer 1/2). The BRCA1 protein is expressed ubiquitously and is likely to play a role in several fundamental processes, including the maintenance of genomic integrity. Paradoxically, BRCA1 appears as a gene essential for proliferation of embryonic cells that simultaneously carries tumor suppressor activity. The nature of the role of BRCA1 in DNA repair and maintenance of genome integrity remains enigmatic. BRCA1 may indeed be a sensor of "abnormal" DNA structures that undergo heterochromatinisation. This model finds some support in the recent report that BRCA1 participates in the maintenance of X-chromosome inactivation, a paradigm for facultative heterochromatinisation. Why are epithelial cells from mammary glands and ovaries the privileged targets for tumorigenesis in women carrying germline mutations in BRCA1? The inheritance of a single defective copy of BRCA1 by women confers a status of susceptibility for developing breast and/or ovarian cancer. The loss of the wild-type allele inherited from the unaffected parent (LOH), commonly observed in the primary breast and ovarian tumors in these susceptible women, represents the event that initiates the tumorigenesis process. This classical two hit model, which assumes that heterozygote cells are "normal" until the LOH occurs stochastically, remains enigmatic.
authors.affiliation: Laboratoire de Génétique Oncologique UMR #8125, Institut Gustave Roussy, Villejuif. feunteun@igr.fr
authors.forename: Jean
authors.initials: J
authors.lastname: Feunteun
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics*; D041321:Chromosomes, Human, X / Q000235:genetics; D005260:Female; D019398:Genes, BRCA1; D006801:Humans; D019656:Loss of Heterozygosity; D010051:Ovarian Neoplasms / Q000235:genetics*
vernacular_title: Un paradoxe et trois énigmes à propos du rôle de BRCA1 dans les cancers du sein et de l'ovaire.